Invivyd, Inc. (Nasdaq: IVVD) announced the pricing of an underwritten public offering of 44,000,000 shares of its common stock at $2.50 per share, with gross proceeds expected to be around $125.0 million. The offering also includes pre-funded warrants to purchase 6,000,000 shares at $2.4999 per warrant. Cantor is the sole book-running manager, and H.C. Wainwright & Co. is the lead manager. The proceeds will be used for commercial preparedness, research and development, and general corporate purposes. The offering is expected to close on or about November 19, 2025.

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company focused on providing protection from serious viral infectious diseases using a proprietary integrated technology platform. In March 2024, Invivyd received emergency use authorization from the U.S. FDA for a monoclonal antibody. The company’s forward-looking statements include details on the offering, its proceeds, timing, and use of net proceeds. Risks and uncertainties surrounding the offering are outlined, with factors that may impact actual results. Invivyd undertakes no duty to update this information, except as required by law.

Read more at GlobeNewswire: Invivyd Announces Pricing of $125 Million Public Offering